NCT06934226

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 752 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	JNJ-77242113	JNJ-77242113 will be administered orally.
DRUG	Matching Placebo to JNJ-77242113	Matching placebo will be administered orally.
DRUG	Ustekinumab	Ustekinumab will be administered subcutaneously.
DRUG	Matching Placebo to Ustekinumab	Matching placebo will be administered subcutaneously.

Timeline

• Start date: 2025-04-15
• Primary completion: 2025-11-17
• Completion: 2027-08-20
• First posted: 2025-04-18
• Last updated: 2026-04-13

Locations

160 sites across 13 countries: United States, Argentina, Australia, Austria, Belgium, Canada, Denmark, Germany, Hungary, Poland, Portugal, Spain, United Kingdom

Regulatory

• FDA-regulated drug study